Each bar is the last disclosed mark — $467.19M for AliveCor (basis undisclosed, Aug 2022) and $350M for MOMA Therapeutics (basis undisclosed, Apr 2023).
At least one valuation basis is undisclosed, so the two numbers stay side by side, each with its own chip, and no ratio is scored. Both are private: there is no public quote and no Canborsa market on either name.
AliveCor was last valued at $467.2M in August 2022, and MOMA Therapeutics at $350M in April 2023.
AliveCor's headquarters is in United States; MOMA Therapeutics' is in United States.
AliveCor employs around 150 people; MOMA Therapeutics employs around 150.
AliveCor is private, and MOMA Therapeutics is private.